Pigmentation Disorder Treatment Market

Pigmentation Disorder Treatment Market Size

Pigmentation Disorder Treatment Market size was valued at USD 7.1 billion in 2023 and is expected to reach USD 11.6 billion by 2032, growing at a CAGR of 5.8% over the analysis period. The increasing prevalence of pigmentation disorder, such as vitiligo, melasma, post-inflammatory hyperpigmentation, coupled with growing awareness among the population is driving the market expansion.

For instance, according to a research article published in the Karger Journal in 2021, individuals with dark skin exhibit a notably high prevalence of pigmentary disorders. The pigmentary disorders rank as the 3rd and 4th most common dermatoses worldwide. Therefore, the high prevalence of pigmentation disorders is anticipated to generate opportunities for market expansion globally.

Pigmentation disorder treatment encompasses a range of medical interventions and procedures designed to address and rectify irregularities in skin pigmentation. These conditions result in alterations of skin, hair, or eye coloration due to changes in the production or distribution of melanin, a pigment responsible for determining skin color. The disorders may include vitiligo, melasma, post-inflammatory hyperpigmentation, albinism, and similar conditions.

Pigmentation Disorder Treatment Market Trends

• The increasing demand for cosmetic procedures especially focusing on skin rejuvenation and achieving an even skin tone, is expected to drive significant growth in the market.
  
• Moreover, pigmentation disorders such as melasma and post-inflammatory hyperpigmentation are among the conditions commonly addressed through aesthetic dermatology treatments. This expansion of aesthetic dermatology services has contributed to the overall growth of the pigmentation disorders treatment market.
  

Pigmentation Disorder Treatment Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on the treatment type, the global market is classified into drugs and procedures. The drugs segment is further bifurcated into type, route of administration, and end users. The segment dominated the market with revenue of USD 4 billion in 2023.

• The segmental growth is owing to increased research and development activities and product launches by major players in the industry. For instance, in July 2022, Ahammune Biosciences formed a partnership with Veeda Clinical Research Limited to conduct clinical trials for AB1001, a drug therapy for vitiligo. This collaboration aims to advance the development of topical treatments and is expected to bolster the growth of the dermatology drugs in the foreseeable future.
  
• Further, administration of corticosteroids is highly recommended for treating pigmentation disorders. Betamethasone valerate, fluticasone propionate, and hydrocortisone butyrate are frequently used corticosteroids. Thus, availability of wide range of drugs in the market is expected to spur the segment growth.
  

Learn more about the key segments shaping this market

Download Free PDF

Based on type of disorder, the pigmentation disorder treatment market is classified into hypopigmentation and hyperpigmentation. The hypopigmentation segment is divided into Vitiligo, Albinism, and other hypopigmentations, whereas the hyperpigmentation segment is divided into Melasma, Lentigines, post-inflammatory hyperpigmentation (PIH) and other hyperpigmentations.

• The hypopigmentation segment is expected to exhibit CAGR of 6.1% between 2024 – 2032 period.
  
• Albinism is a rare set of genetic disorders characterized by reduced or absent pigmentation in the skin, hair, or eyes. The high segmental growth is primarily due to the increasing prevalence of albinism. For instance, as per an article published in August 2022 by StatPearls, it was disclosed that the American region exhibited the significant occurrence of oculocutaneous albinism type 2, with a prevalence rate of 1 in 36,000. Thus, with the increasing prevalence of albinism, the surge in demand for treatments targeting pigmentation disorders is expected to spur the growth of this segment.
  

Looking for region specific data?

Download Free PDF

In 2023, North America region held a market share of 42.2% in the global pigmentation disorder treatment market and is expected to dominate throughout the forecast period.

• High regional market growth can be attributed to the high healthcare expenditure, advanced healthcare infrastructure in the region, and increase in the skin procedures are contributing to the demand for pigmentation disorder treatment.
  
• For instance, according to data from the Aesthetic Plastic Surgery National Databank in April 2022, the U.S. recorded about 1.3 million skin treatment procedures in 2021, which included hydro facials, chemical peels, and others. This high incidence of cosmetics is expected to drive regional growth.
  
• Additionally, the presence of prominent market players and extensive research and development activities in the region, further drive market expansion.
  

Pigmentation Disorder Treatment Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their business portfolios. Also, the companies are actively adopting a multi-pronged approaches to address the rising demand for effective pigmentation disorder treatment.

Pigmentation Disorder Treatment Market Companies

Prominent players operating in the pigmentation disorder treatment industry are as mentioned below:

• AbbVie Inc.
• Candela Corporation
• Cipher Pharmaceuticals Inc.
• Galderma
• GlaxoSmithKline (GSK)
• Incyte
• L'Oréal Paris
• Novartis AG
• Pfizer Inc.
• Pierre Fabre group
• Shiseido Company Limited
  

Pigmentation Disorder Treatment Industry News:

• In July 2022, Incyte Corporation received the U.S. Food and Drug Administration (FDA) approval Opzelura (ruxolitinib) cream 1.5% for the treatment of non-segmental vitiligo. Opzelura is the first and only FDA-approved product for repigmentation in non-segmental vitiligo, and its approval was based on data from the pivotal Phase 3 TRuE-V clinical trial program. The FDA approval allowed Opzelura to be prescribed for continuous topical use. The approval helped the company hold a competitive edge in the field of vitiligo treatment.
  
• In October 2021, Uniza Group launched a novel solution Vitellus a combination of Greyverse, Melitane, GL 200, and EUK-134 in the Indian market. Vitellus is a 3-in-1 solution that helps in melamine growth, skin pigmentation, and hair follicle pigmentation, and also acts as a super antioxidant. This helped company enhance its product offering and strengthen its market position.
  

The pigmentation disorder treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Drugs
  • By type
    • Corticosteroids
    • Melanocyte-stimulating hormone
    • Other drugs
  • By route of administration
    • Oral
    • Topical
    • Other routes of administration
  • By distribution channel
    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies
• Procedures
  • By type
    • Laser treatment
    • Phototherapy
    • Dermabrasion
    • Other procedures
  • By end-user
    • Hospitals
    • Dermatology clinics
    • Aesthetic centers
    • Other end-users

Market, By Type of Disorder

• Hypopigmentation
  • Vitiligo
  • Albinism
  • Other hypopigmentations
• Hyperpigmentation
  • Melasma
  • Lentigines
  • Post-inflammatory hyperpigmentation (PIH)
  • Other hyperpigmentations

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa